Investigational drug · Phase 3
[18F]FAPI-74 PET
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
n/a
Any phase or sponsor naming "[18F]FAPI-74 PET"
First trial start
2023
Apr 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "[18F]FAPI-74 PET", any sponsor or status.
Conditions studied
As listed on its trial records.
- Esophageal Cancer
- Gastric Cancer (GC)
- Gastroesophageal Junction
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Gastrointestinal Cancers
- Cholangiocarcinoma
- Gastric Cancer
- Colorectal Cancer
- Pancreatic Ductal Adenocarcinoma
- Hepatocellular Carcinoma
Approved drugs for the same conditions: Colorectal cancer · Pancreatic cancer · Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "[18F]FAPI-74 PET" as an intervention, largest first.
- Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
NCT07217704 · Phase 3 · Recruiting · SOFIE · 200 participants · primary completion Aug 30, 2027
- Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07217717 · Phase 3 · Recruiting · SOFIE · 200 participants · primary completion Dec 31, 2027
- Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
NCT05641896 · Phase 2 · Completed · SOFIE · 112 participants · primary completion Jun 30, 2025
Newest research
PubMed records naming it or its code names, newest first.
- Fibroblast activation protein inhibitor-PET/CT in lung cancer: a prospective single-center study with histopathological correlation of fibroblast activation protein expression.
Hiroshima T, Kimura T, Watabe T, et al. · Int J Clin Oncol 2026
Also in development for Esophageal Cancer
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
- PetosemtamabMCLA-158, GEN1158Phase 35 trials
Genmab · Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Advanced/Metastatic Solid Tumors
- LerotinibZ650Phase 31 trial
Sunshine Lake Pharma Co., Ltd. · Esophageal Cancer
- SI-B003Phase 210 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
- TQB6411Phase 22 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Advanced Lung Cancer, Esophageal Cancer
- IMT-009Phase 21 trial
Immunitas Therapeutics · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.